Login to Your Account

Epizyme, Glaxo Explore Epigenetics in $630M Deal

By Catherine Shaffer

Tuesday, January 11, 2011
Under a new partnership agreement between the two companies, GlaxoSmithKline plc will leverage Epizyme Inc.'s histone methyltransferase (HMT) platform to explore epigenetic targets for cancer therapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription